Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Provides Business Update FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition...
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2...
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred...
– Reports audited financial results for the Fourth Quarter and Full Year ended December 31, 2019 – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) ("Cannara") to a...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”) (collectively, the “Parties”), are pleased to announce that, further...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 16.225 | 16.225 | 16.225 | 976 | 16.225 | DE |
| 4 | 0 | 0 | 16.225 | 16.225 | 16.225 | 2085 | 16.225 | DE |
| 12 | 0 | 0 | 16.225 | 16.225 | 16.225 | 1747 | 16.225 | DE |
| 26 | 0 | 0 | 16.225 | 16.225 | 16.225 | 1553 | 16.225 | DE |
| 52 | 0 | 0 | 16.225 | 16.225 | 16.225 | 12084 | 16.225 | DE |
| 156 | 8.625 | 113.486842105 | 7.6 | 20.21 | 7.151 | 82092 | 14.60909745 | DE |
| 260 | 5.825 | 56.0096153846 | 10.4 | 20.21 | 6.2125 | 89352 | 11.69528262 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
